<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441530</url>
  </required_header>
  <id_info>
    <org_study_id>BezmialemVU</org_study_id>
    <nct_id>NCT02441530</nct_id>
  </id_info>
  <brief_title>Effectiveness of Vitamin D in Primary Dysmenorrhoea</brief_title>
  <official_title>Vitamin D in the Treatment of Primary Dysmenorrhoea: A Prospective Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seda Ates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osman Sevket</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mucize Ozdemir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gulsah Ilhan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yildirim, Zeynep Baysal, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D in the treatment of primary dysmenorrhoea. Design:Randomised controlled trial.
      Setting:In a university hospital. Population: 142 women aged 16-35 years. Methods: Patients
      were treated with 667 unit of vitamin D once a day, 200 unit of vitamin E once a day or 400
      mg ibuprofen twice a day,2 days before the date of menstruation and continued through the
      first 3 days, for 2 months. Main outcome measures: Pain score. Results: Mean VAS of vitamin D
      group was 4,91, was 6,54 in the vitamin E group and was 4,02 in the ibuprofen group
      Conclusion:Vitamin D and vitamin E are effective in relieving the pain,but the effect of
      vitamin D are more prominent
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An excessive uterine production of prostaglandins is the pathogenic trigger of dysmenorrhoea.
      Nonsteroidal anti-inflammatory drugs (NSAIDs) are the currently accepted drugs for the
      management of this disorder. The capacity for synthesizing vitamin D and the presence of
      vitamin D receptor in human cycling endometrium have also been demonstrated. Because vitamin
      D reduces the synthesis of prostaglandins, a beneficial effect of vitamin D for the uterus is
      possible.Vitamin E inhibits the release of arachidonic acid and the conversion of arachidonic
      acid to prostaglandin via an action on the enzymes phospholipase A2 and cyclooxygenase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain score ,make a mark on a 10-cm visual analog scale (VAS)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Primary Dysmenorrhoea</condition>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>vitamin D</arm_group_label>
    <other_name>Devit-3 damla barcod number 8699525590435 ,DEVA Holding AŞ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <arm_group_label>vitamin E</arm_group_label>
    <other_name>Evicap d-alfa-Tokoferol, KOÇAK Farma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>profen Dinçtaş İlaç</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women had regular menstrual cycles lasted 21 to 35 days, with menstruation lasting 3
             to 7 days;

          2. Women had to be in good health and taking no medications including calcium, magnesium,
             vitamin D and oral contraceptives.

          3. Women had not a previous history of gynaecological disease, and a normal pelvic
             examination were eligible.

        Exclusion Criteria:

        1) Previous and current use of intrauterine contraceptive devices within the 6 months to
        enrollment was not permitted
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bezmialem Vakif University</investigator_affiliation>
    <investigator_full_name>Aysegül Özel</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

